Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 06:40 am Purchase | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BCLS II Equity Opportunities LP | 113,908 5.800% | 5,908 (+5.47%) | Filing History |
| 2022-02-11 4:12 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 158,245 7.900% | -42,376 (-21.12%) | Filing History |
| 2022-02-10 5:03 pm Purchase | 2022-02-09 | 13D | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 201,779 9.900% | 5,732 (+2.92%) | Filing History |
| 2022-02-10 4:13 pm Purchase | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ELI LILLY & Co LLY | 61,061 3.100% | 61,061 (New Position) | Filing History |
| 2022-02-10 11:14 am Purchase | 2022-02-09 | 13G | Spyre Therapeutics, Inc. SYRE | PICTET ASSET MANAGEMENT SA | 98,725 5.000% | 98,725 (New Position) | Filing History |
| 2022-02-10 09:01 am Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ADAGE CAPITAL PARTNERS GP L.L.C. | 40,000 2.030% | -79,680 (-66.58%) | Filing History |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 119,939 6.100% | -9,660 (-7.45%) | Filing History |
| 2021-12-16 4:32 pm Purchase | 2021-12-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE | SUVRETTA CAPITAL MANAGEMENT LLC | 102,840 5.200% | 102,840 (New Position) | Filing History |
| 2021-03-19 4:07 pm Purchase | 2021-03-16 | 13D | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 196,048 9.900% | 346 (+0.18%) | Filing History |
| 2021-03-05 5:17 pm Unchanged | 2021-02-23 | 13D | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 195,701 9.900% | 0 (Unchanged) | Filing History |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 195,701 9.900% | 127,157 (+185.51%) | Filing History |
| 2021-02-16 3:14 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Point72 Asset Management, L.P. | 117,191 6.100% | 1,672 (+1.45%) | Filing History |
| 2021-02-16 10:21 am Sale | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Nantahala Capital Management, LLC | 96,560 4.900% | -17,530 (-15.37%) | Filing History |
| 2021-02-12 4:59 pm Sale | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Lilly Ventures Fund I LLC | 102,742 5.400% | -3,227 (-3.04%) | Filing History |
| 2021-02-12 4:39 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 200,621 10.250% | 86,000 (+75.03%) | Filing History |
| 2021-02-11 07:31 am Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ADAGE CAPITAL PARTNERS GP L.L.C. | 119,680 6.240% | 60,936 (+103.73%) | Filing History |
| 2021-02-10 11:37 am Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | PICTET ASSET MANAGEMENT SA | 100,773 5.250% | 100,773 (New Position) | Filing History |
| 2021-02-10 06:35 am Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | LV Management Group LLC | 4,141 0.200% | 4,141 (New Position) | Filing History |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 129,599 6.800% | 53,107 (+69.43%) | Filing History |
| 2020-10-26 4:36 pm Purchase | 2020-10-23 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Point72 Asset Management, L.P. | 115,519 6.200% | 115,519 (New Position) | Filing History |